For 35 years scientists have known that naturally occurring compounds in the cannabis plant possess potent and selective anti-cancer properties, a fact that I have documented extensively in previous writings.
Yet for more than three decades the scientific study of these anti-cancer effects has remained almost exclusively limited to preclinical in vitro (in a petri dish) and in vivo (in lab animals) analysis, rather than clinical (human) study. Why? A just published review in the Journal of Pharmacy and Pharmacology provides an answer.
Sounds promising, huh? Well it is — that is, until you get to this:
And just what are these terrible “unwanted effects” — effects so “problematic” that we must continue to forbid scientists from clinically studying the drug’s effects in cancer patients? I’ll let the authors explain.
You read that right. The ‘problem’ with cannabinoids anti-cancer abilities is that patients might temporarily feel better after they take them!
Now contrast mainstream science’s feigned concern with the so-called ‘unwanted effects’ of the natural cannabis ‘high’ with the actual side-effects of the pharmaceutical cannabinoid antagonist drug rimonabant (aka Acomplia), which was recently withdrawn from the European market because of the the drug’s link to depression and suicide.
Let’s review shall we? Natural plant selectively kills cancer, but it may also get you high = “problematic.” Synthetic pharmaceutical drug short circuits the body’s natural endocannabinoid system and will likely make you depressed and suicidal = “opportune.”
Fri, 17 Jul 2009 22:53:05 By: Paul Armentano, NORML Deputy Director